Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

NanoViricides, Inc. (NNVC) Announces Updates on Completed Animal Study for Anti-HIV Candidate

|Includes: NanoViricides, Inc. (NNVC)

Today, NanoViricides, Inc. reported updates on the completed animal study that compared its lead anti-HIV candidate, HIVCide™, to a highly active anti-retroviral therapy (HAART) triple drug cocktail, which is based on an anti-HIV therapeutic protocol currently in practice. NanoViricides’ reports come after receiving many inquiries for a simplified explanation of the results.

The company believes that the anti-HIV nanoviricide acts by a different mechanism than all the current components of HAART therapy regimens. Instead, the company has theorized that the nanoviricide binds to a virus particle by mimicking the cellular structures to which the virus binds, as explained in the July 27 press release. As such, NanoViricides anticipates that the HIVCide would be able to complement almost any of the various HAART therapy regimens and provide additional therapeutic benefits. Further, NanoViricides believes that such a combination therapy that includes HIVCide would possibly achieve a “functional cure” of HIV/AIDS, the penultimate goal of all HIV/AIDS research.

As NanoViricides further explained, after such a treatment protocol, the patient would be able to stop the treatment and lead a normal life, until a recurrence occurs by reactivation of HIV from the “sleeping” reservoir cells that contain HIV retroviral DNA. Upon such recurrence, the same therapy or a modified regimen could bring about a new disease-free period for the patient. This is somewhat akin to what happens with herpesviral infections at present. While current HSV therapies do not eliminate the herpes virus completely, they provide disease-free periods until next recurrence.

The company believes that it can rapidly improve its lead HIVCide candidate further, using its proven lead optimization technology. If such improvements can be made, the resulting drug therapy could provide substantial additional benefits.

Eugene Seymour, MD, MPH, the CEO of NanoViricides, remarked, “An example of the success of our ‘lead optimization technology’ was the dramatic improvement noted in results obtained with FluCide™ for influenza. Over only a few cycles of optimization the Company has substantially improved effectiveness of its anti-influenza drug candidates.”

He added, “We now intend to apply the same optimization techniques to our lead anti-HIV candidate.”

Please see disclaimer on the QualityStocks website: